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Therapies targeting T cell immune checkpoints such as
CTLA4 and PD1/PDL1 axis have shown considerable
promise in the therapy of human cancer. Combination
therapy with dual immune checkpoint blockade (ICB)
was recently shown to be highly active in melanoma.
While signaling via both PD1 and CTLA4 is known to
converge downstream and dampen T cell function, data
comparing in vivo effects of blockade of these immune
checkpoints either alone or in combination in vivo in
humans are limited. Here we have analyzed paired pre/
post therapy samples from patients treated either anti-
CTLA4 (n = 5) or anti-PD1 (n = 6) alone, or a combina-
tion of anti-CTLA4 and anti-PD1 (n = 8), using several
methodologies including multi-parameter flow cytome-
try, single-cell mass-cytometry (CyTOF), Luminex and
analysis of transcriptome of purified immune cells with
exon-level arrays. We show that blockade of CTLA4,
PD1 or combination blockade leads to distinct immuno-
logic, genomic and cytokine signatures in vivo. CTLA4
blockade leads to a prominent proliferation signature in
vivo, manifest as an increase in Ki-67 expression in a
subset of T cells with transitional memory phenotype.
PD1 blockade does not induce this phenotype and
instead leads to marked changes in T cells expressing
NK and cytolysis associated genes, as exemplified by
Granzyme+ T cells. Combination blockade leads to non-
overlapping changes in gene expression including prolif-
eration-associated and chemokine genes and leads to an
increase in both Ki67+and Granzyme+ T cells. Overall,
therapy-induced changes are more prominent in T cells
than in monocytes include also involve non-overlapping
changes in several alternatively spliced transcripts and
non-coding RNAs. Each of the ICB therapies also leads
to a distinct cytokine profile with differential effects on
systemic levels of sIL2R and IL1a. Changes seen in the
peripheral blood T cells can also be seen in the tumor
infiltrating lymphocytes. Combination therapy leads to
an increase in interferon-gamma producing T cells in
both circulation as well as tumor bed. PD1 expression is
higher on tumor infiltrating T cells when compared to
T cells in circulation. Importantly, PD1 receptor occu-
pancy following anti-PD1 therapy may be incomplete in
the tumor infiltrating T cells even in the setting of com-
plete receptor occupancy in circulating T cells. These
data demonstrate that blockade of PD1, CTLA4 alone
or in combination have distinct immunologic effects in
vivo and each strategy serves as a unique immune-thera-
peutic. Improved understanding of the in vivo effects of
ICB is needed for rational development of future immune-
based combinations against cancer.
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